Department of Pathology, Nanfang Hospital and School of Basic Medical Science, Southern Medical University, 1838, Guangzhoudadao Rd, Guangzhou, Guangdong Province, 510515, People's Republic of China.
Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou, 510515, Guangdong Province, People's Republic of China.
BMC Cancer. 2021 Aug 12;21(1):915. doi: 10.1186/s12885-021-08594-x.
Intracranial hemangiopericytoma is a rare disease and surgery is the mainstay treatment. Although postoperative adjuvant radiotherapy is often used, there are no reports comparing different radiotherapy techniques. The purpose of this study is to analyze the impact of post-operative radiotherapy and different radiotherapy technique on the results in patients with intracranial hemangiopericytoma (HPC).
We retrospectively reviewed 66 intracranial HPC patients treated between 1999 and 2019 including 29 with surgery followed by radiotherapy (11 with intensity-modulated radiotherapy (IMRT) and 18 with stereotactic radiosurgery (SRS)) and 37 with surgery alone. Chi-square test was used to compare the clinical characteristic between the groups. The Kaplan-Meier method was used to analyze overall survival (OS) and recurrence-free survival (RFS). Multivariate Cox proportional hazards models were used to examine prognostic factors of survival. We also underwent a matched-pair analysis by using the propensity score method.
The crude local control rates were 58.6% in the surgery plus post-operative radiotherapy group (PORT) and 67.6% in the surgery alone group (p = 0.453). In the subgroup analysis of the PORT patients, local controls were 72.7% in the IMRT group and 50% in the SRS group (p = 0.228). The median OS in the PORT and surgery groups were 122 months and 98 months, respectively (p = 0.169). The median RFS was 96 months in the PORT group and 72 months in the surgery alone group (p = 0.714). Regarding radiotherapy technique, the median OS and RFS of the SRS group were not significantly different from those in the IMRT group (p = 0.256, 0.960). The median RFS were 112 and 72 months for pathology grade II and III patients, respectively (p = 0.001). Propensity score matching did not change the observed results.
In this retrospective analysis, PORT did not improve the local control rates nor the survivals. The local control rates after IMRT and SRS were similar even though the IMRT technique had a much higher biological dose compared with the SRS technique.
颅内血管外皮细胞瘤是一种罕见疾病,手术是主要的治疗方法。虽然术后常采用辅助放疗,但尚无比较不同放疗技术的报道。本研究旨在分析术后放疗和不同放疗技术对颅内血管外皮细胞瘤(HPC)患者结果的影响。
我们回顾性分析了 1999 年至 2019 年间治疗的 66 例颅内 HPC 患者,其中 29 例接受手术加放疗(11 例采用调强放疗(IMRT),18 例采用立体定向放疗(SRS)),37 例仅接受手术治疗。采用卡方检验比较两组的临床特征。采用 Kaplan-Meier 法分析总生存期(OS)和无复发生存期(RFS)。采用多变量 Cox 比例风险模型分析生存的预后因素。我们还通过倾向评分匹配法进行了配对分析。
手术加术后放疗组(PORT)的粗局部控制率为 58.6%,单纯手术组为 67.6%(p=0.453)。在 PORT 患者的亚组分析中,IMRT 组的局部控制率为 72.7%,SRS 组为 50%(p=0.228)。PORT 组和手术组的中位 OS 分别为 122 个月和 98 个月(p=0.169)。PORT 组的中位 RFS 为 96 个月,单纯手术组为 72 个月(p=0.714)。关于放疗技术,SRS 组和 IMRT 组的中位 OS 和 RFS 无显著差异(p=0.256,0.960)。病理分级为 II 级和 III 级的患者中位 RFS 分别为 112 个月和 72 个月(p=0.001)。倾向评分匹配并未改变观察结果。
在这项回顾性分析中,PORT 并未提高局部控制率和生存率。即使 IMRT 技术的生物剂量明显高于 SRS 技术,IMRT 和 SRS 后的局部控制率相似。